*Based on an analysis of comparative clinical studies that roughly established an equivalent dose for phosphate binders relative to the phosphate binding capacity of calcium carbonate.1

A retrospective analysis of deidentified clinical and prescription data from 818 hemodialysis patients extracted from the Fresenius Kidney Care clinical data warehouse and Fresenius pharmacy database. Clinical and laboratory parameters of 222 patients who continued Velphoro monotherapy for 24 months from baseline beginning between April 1, 2014, and April 1, 2015, were compared to 596 patients who discontinued Velphoro and were switched to alternate phosphate binders within 90 days of baseline. The decision to switch phosphate binders was made on a clinical basis and the reasons underlying this change were not available. Outcomes included achievement of target serum phosphorus of ≤5.5 mg/dL and phosphate binder pill burden.2

References: 1. Coyne DW, Larson DS, Delmez JA. Bone disease. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 5th ed. Wolters Kluwer Health; 2015:665-692. 2. Coyne DW, Ficociello LH, Parameswaran V, et al. Sucroferric oxyhydroxide in maintenance hemodialysis: a retrospective, comparative cohort study. Kidney Med. 2020;2(3):307-316. 3. Velphoro®  [package insert]. Waltham, MA: Fresenius Medical Care North America; 2020. 4. Data on file. Fresenius Medical Care North America. Waltham, MA. 5. Medicare.gov. https://www.medicare.gov/sites/default/files/2021-08/11324%20Extra-Help-Pay-Right-Amount.pdf. Accessed September 23, 2021.